Lixte Biotechnology Holdings Inc./$LIXT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
Ticker
$LIXT
Sector
Primary listing
Employees
3
Headquarters
Website
LIXT Metrics
BasicAdvanced
$39m
-
-$1.26
0.95
-
Price and volume
Market cap
$39m
Beta
0.95
52-week high
$6.26
52-week low
$0.64
Average daily volume
42k
Financial strength
Current ratio
3.884
Quick ratio
3.831
Long term debt to equity
4.005
Total debt to equity
9.436
Interest coverage (TTM)
-557.72%
Profitability
Management effectiveness
Return on assets (TTM)
-46.00%
Return on equity (TTM)
-101.95%
Valuation
Price to book
3.73
Price to tangible book (TTM)
3.73
Price to free cash flow (TTM)
-5.153
Free cash flow yield (TTM)
-19.41%
Free cash flow per share (TTM)
-0.654
Growth
Earnings per share change (TTM)
-21.24%
3-year earnings per share growth (CAGR)
-31.98%
10-year earnings per share growth (CAGR)
-10.14%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lixte Biotechnology Holdings Inc. stock?
Lixte Biotechnology Holdings Inc. (LIXT) has a market cap of $39M as of May 04, 2026.
What is the P/E ratio for Lixte Biotechnology Holdings Inc. stock?
The price to earnings (P/E) ratio for Lixte Biotechnology Holdings Inc. (LIXT) stock is 0 as of May 04, 2026.
Does Lixte Biotechnology Holdings Inc. stock pay dividends?
No, Lixte Biotechnology Holdings Inc. (LIXT) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Lixte Biotechnology Holdings Inc. dividend payment date?
Lixte Biotechnology Holdings Inc. (LIXT) stock does not pay dividends to its shareholders.
What is the beta indicator for Lixte Biotechnology Holdings Inc.?
Lixte Biotechnology Holdings Inc. (LIXT) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.